Anke Biotechnology: The application for the registration and marketing authorization of Acetate Exenatide Injection has been accepted.

Anke Biotechnology announced that the company has received the Administrative Licensing Document "Acceptance Notification" from the National Medical Products Administration. The application for the registration and marketing authorization of injectable Acetate Cetrorelix has been accepted. This drug is a third-generation gonadotropin-releasing hormone antagonist, indicated for preventing premature ovulation in assisted reproductive technology. It offers advantages such as rapid onset of action and a low incidence of ovarian hyperstimulation syndrome and adverse events. The acceptance of this application is only a milestone in the new drug development process, and there is still uncertainty regarding whether it will be approved for marketing.